Translational PBPK Modeling and Exposure‐Response Analysis of AT ‐ RvD1 for Treating Sjögren's Disease
Clinical and Translational Science · 2026
DOI: 10.1111/cts.70741 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Venkata K Yellepeddi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA. Hauptthemen laut MEDLINE: Sjogren's Syndrome, Models, Biological, Fatty Acids. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIDCR NIH HHS, National Institutes of Health-National Institute of Dental and Craniofacial Research.
Abstract (Originalsprache)
Sjögren's disease (SD) is an autoimmune condition characterized by chronic inflammation and impaired secretory function of the salivary glands (SG). The proresolving lipid mediator AT‐RvD1 restores SG function in SD‐like mice; however, its tissue pharmacokinetics, exposure‐response relationships, and human dose predictions remain poorly understood. Therefore, this exploratory study characterizes AT‐RvD1 tissue pharmacokinetics, develops an SG‐focused physiologically based pharmacokinetic (PBPK) model, explores the relationship between SG exposure and secretory response, and predicts human exposures relevant to clinical development. Following intravenous administration of AT‐RvD1 to SD‐like mice, concentrations were quantified in serum, submandibular gland (SMG), heart, lung, liver, and kidney. These data were used to evaluate a PBPK model incorporating the SG as the target site of action. PBPK‐predicted cumulative SMG exposure was subsequently compared with the saliva flow rate obtained after chronic AT‐RvD1 treatment. The mouse model was then used to predict systemic and SG exposure in a virtual human population across an exploratory dose range. The PBPK model described systemic and tissue pharmacokinetics, with average fold error and absolute average fold error values within predefined acceptance criteria. Human PBPK simulations predicted dose‐dependent increases in SG exposure and identified 1.5 mg/kg as a candidate dose at which predicted concentrations exceeded the preclinical pharmacological reference concentration in more than 90% of simulated subjects. Collectively, these analyses provide an experimentally informed PBPK framework for exploring AT‐RvD1 tissue exposure, exposure–response relationships, and candidate doses for future clinical evaluation in SD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Clinical Pharmacology, Department of Pediatrics, Spencer Fox Eccles School of Medicine, University of Utah, Salt Lake City, Utah, USA.
- Department of Molecular Pharmaceutics, College of Pharmacy, University of Utah, Salt Lake City, Utah, USA.
- Christopher S. Bond Life Sciences Center, Columbia, Missouri, USA.
- Department of Otolaryngology-Head and Neck Surgery, School of Medicine, University of Missouri, Columbia, Missouri, USA.
- Department of Biochemistry, School of Medicine, University of Missouri, Columbia, Missouri, USA.
ORCID-Profile: Venkata K Yellepeddi, Kihoon Nam, Frank M Maslow, Olga J Baker
Förderung
- NIDCR NIH HHS
- National Institutes of Health-National Institute of Dental and Craniofacial Research
Zitieren
APA
Yellepeddi, V. K., Nam, K., Maslow, F. M., & Baker, O. J. (2026). Translational PBPK Modeling and Exposure‐Response Analysis of AT ‐ RvD1 for Treating Sjögren's Disease. Clinical and Translational Science. https://doi.org/10.1111/cts.70741
Vancouver
Yellepeddi VK, Nam K, Maslow FM, Baker OJ. Translational PBPK Modeling and Exposure‐Response Analysis of AT ‐ RvD1 for Treating Sjögren's Disease. Clinical and Translational Science. 2026. doi:10.1111/cts.70741
BibTeX
@article{Yellepeddi2026,
author = {Yellepeddi, Venkata K and Nam, Kihoon and Maslow, Frank M and Baker, Olga J},
title = {Translational PBPK Modeling and Exposure‐Response Analysis of AT ‐ RvD1 for Treating Sjögren's Disease},
journal = {Clinical and Translational Science},
year = {2026},
doi = {10.1111/cts.70741}
}
EUVIMED